On this page
Key takeaways
• Liposomal fisetin is marketed as more bioavailable than unformulated capsules. The theoretical basis is sound; direct human pharmacokinetic data specific to commercial liposomal fisetin products remain limited.
• The Krishnakumar 2022 hydrogel formulation (not liposomal) produced a 23-fold Cmax improvement in humans (1). This is proof that formulation can meaningfully improve fisetin absorption.
• A 2025 cell-culture study reported that fisetin-loaded liposomes lost senolytic activity and instead suppressed the Senescence-Associated Secretory Phenotype — a shift from senolytic to senomorphic pharmacology (3).
• Senolytic and senomorphic are different mechanisms. A senolytic kills senescent cells. A senomorphic silences their inflammatory secretions. Which one you want depends on your goals.
• Liposomal, phytosomal, nanoemulsion, and hydrogel are distinct formulation approaches with different pharmacokinetic and pharmacological profiles. "Enhanced absorption" is a marketing category, not a specific pharmacology.
• Bioavailability improvement is not the same as clinical efficacy improvement. No head-to-head human trial has yet demonstrated that liposomal fisetin produces better clinical outcomes than unformulated fisetin at equivalent doses.
Quick answer
Liposomal fisetin is a formulation strategy that improves fisetin’s poor oral bioavailability. The general case for enhanced formulations is strong — the Krishnakumar 2022 study demonstrated a 23-fold plasma concentration improvement with a hydrogel formulation (1). But a 2025 cell-culture study reported that fisetin-loaded liposomes specifically may lose the senolytic activity that made fisetin famous, instead shifting to a senomorphic (SASP-suppressing) profile (3). This changes what fisetin does at the cellular level, not just how much reaches the bloodstream. Whether this matters for a given reader depends on whether they are pursuing senescent-cell clearance (favouring unformulated pulsed dosing) or general inflammatory-signal reduction (potentially favouring liposomal daily dosing). This article walks through the pharmacology, the marketing landscape, and the honest decision framework.
The general case for enhanced formulations
Fisetin’s oral bioavailability is poor. An unformulated 1,000 mg dose produces a peak plasma concentration of just 9.97 ng/ml in healthy adults — 30 to 150-fold below the in vitro senolytic window (1). See our dedicated bioavailability article for the full pharmacokinetic detail.
Formulation strategies target this ceiling in several ways: improving aqueous solubilisation (so more fisetin dissolves and can enter the enterocyte), protecting the parent compound from first-pass metabolism (so more fisetin reaches systemic circulation intact), and improving lymphatic delivery (so fisetin bypasses the hepatic portal circulation and its extensive first-pass metabolism). Different formulation approaches address different limits.
|
Formulation type |
Primary mechanism |
Evidence base |
|
Hydrogel (galactomannan-based) |
Improved aqueous dispersion + lymphatic absorption |
23-fold Cmax in humans (1) |
|
Liposomal |
Phospholipid encapsulation, improved membrane transit |
Preclinical only; may shift pharmacology (3) |
|
Nanoemulsion |
Fine oil droplets, improved solubilisation |
4–24-fold Cmax in animal studies (4) |
|
Polymeric nanoparticle |
Controlled release, protection from metabolism |
|
|
Phytosome (phospholipid complex) |
Phospholipid-flavonoid complex, improved membrane transit |
Extrapolated from curcumin phytosome literature |
|
Piperine co-formulation |
CYP450 inhibition, reduced first-pass metabolism |
Extrapolated from curcumin data |
The hydrogel formulation used in Krishnakumar 2022 is the only formulation with direct human pharmacokinetic evidence in the peer-reviewed literature (1). All others draw on animal data, cell-culture data, or extrapolation from related flavonoids. This does not mean the others do not work — pharmaceutical formulation science is transferable across compound classes — but it does mean that specific efficacy claims for specific liposomal fisetin products are usually not backed by product-specific human PK data.
The 2025 senolytic-to-senomorphic study
The Molagoda 2025 paper is the most consequential recent publication on liposomal fisetin, and it complicates the marketing story significantly (3).
The study prepared fisetin-loaded liposomes and tested them against senescent human dermal fibroblasts (an ex vivo cell model of aged skin cells). The comparison was against unencapsulated fisetin at equivalent nominal concentrations. Two findings emerged.
First, the liposomal fisetin was more effective than unencapsulated fisetin at reducing SASP factor secretion — specifically IL-6 and IL-8. This is a senomorphic effect: silencing the inflammatory output of senescent cells without killing them.
Second, and more strikingly, the liposomal fisetin did not produce the selective apoptosis of senescent cells that unencapsulated fisetin produces. The liposomal formulation lost the senolytic identity. The cells that had become senescent remained senescent — they just secreted fewer inflammatory factors.
The mechanistic interpretation offered by the authors is that liposomal encapsulation changes intracellular trafficking of fisetin. Instead of reaching the concentrations that trigger senolytic apoptosis, liposomally delivered fisetin distributes more evenly and produces senomorphic effects at lower intracellular concentrations. This is a fundamentally different pharmacology, not just a different pharmacokinetic profile.
Why this matters — the senolytic vs senomorphic distinction
Senolytic and senomorphic are related pharmacological categories with different implications for a reader.
Senolytic pharmacology
A senolytic kills senescent cells outright. The senescent-cell population is reduced. Downstream benefits — reduced SASP, reduced inflammaging, reduced tissue dysfunction — accrue over weeks after each pulse and require repeat pulses on the 28-day cycle to sustain. This is the mechanism the Mayo Clinic trials are testing, and it is the mechanism that produced the mouse lifespan extension in Yousefzadeh 2018 (2). Fisetin’s original identity.
Senomorphic pharmacology
A senomorphic does not kill senescent cells; it silences their inflammatory secretions. The senescent-cell population remains, but its harmful output is reduced. Rapamycin and metformin have documented senomorphic activity. Benefits require sustained exposure — as soon as the senomorphic drug is withdrawn, the SASP resumes. The pharmacology is closer to a chronic anti-inflammatory than to a hit-and-run senolytic.
For a reader specifically pursuing senolytic activity (clearance of senescent cells), the Molagoda 2025 data suggest that liposomal fisetin may not be the right vehicle — unformulated pulsed dosing may better preserve the senolytic identity, even at the cost of poor bioavailability. For a reader pursuing general inflammatory-signal reduction (SASP suppression, mild systemic anti-inflammatory effect), liposomal fisetin at daily doses may be a defensible choice.
Neither conclusion is definitive — Molagoda 2025 is a cell-culture study, not a human trial, and the specific liposomal formulation tested is not commercially available. Different commercial liposomal fisetin products may behave differently. But the finding is important enough that consumers should be aware of it. It is not simply the case that liposomal fisetin is a better version of the same drug; it may be a pharmacologically different drug.
The commercial landscape — what to look for
Multiple commercial products advertise "liposomal fisetin" or related formulation categories. The marketing language is not standardised, and product-specific pharmacokinetic data are almost universally absent. Four questions help separate the marketing from the pharmacology.
1. Is there product-specific human PK data?
Rarely. The Krishnakumar 2022 hydrogel formulation is the only fisetin formulation with published human PK data in a peer-reviewed journal (1). Most "liposomal" or "phytosomal" fisetin products cite general liposome pharmacology or extrapolate from curcumin-phytosome studies. This is not the same as product-specific evidence.
2. What is the actual formulation?
"Liposomal" is a category, not a specific formulation. Real liposomes are lipid bilayer vesicles that entrap the compound; some products marketed as "liposomal" are actually phytosomes (phospholipid complexes), micelles, or emulsions. These are pharmacokinetically distinct. A supply-chain-transparent product will disclose the specific formulation strategy.
3. Does the product deliver senolytic doses in pulses, or lower doses continuously?
Liposomal fisetin is typically sold at lower per-capsule doses on the theory that improved absorption reduces the required dose. If the goal is senolytic activity as tested in the Mayo Clinic trials, matching the pulsed protocol (20 mg/kg × 2 days) with a bioavailability-enhanced formulation would require substantially smaller absolute doses — but this specific approach has not been tested in a human trial.
4. What does the third-party Certificate of Analysis show?
For any fisetin product, but particularly for formulated products where marketing claims often outrun the evidence, a batch-specific Certificate of Analysis from an ISO 17025-accredited laboratory is the load-bearing quality signal. Independent testing has repeatedly found that commercial fisetin powders can contain substantially less fisetin than the label states. Our best fisetin supplement article walks through the criteria.
What we still don't know
• Whether any specific commercial liposomal fisetin product produces better clinical outcomes than unformulated capsules. No head-to-head human trial has been reported.
• Whether the senolytic-to-senomorphic shift observed in Molagoda 2025 applies to all liposomal formulations or only to the specific one tested. Different liposomal preparations may behave differently (3).
• Whether the improved bioavailability of formulated fisetin allows lower-dose pulsed protocols to achieve the tissue concentrations the unformulated 20 mg/kg protocol targets. This has not been formally tested in humans.
• How the shift from senolytic to senomorphic pharmacology plays out over months of continuous liposomal dosing. The 2025 cell-culture data give a mechanistic snapshot; the whole-organism story is unknown.
• Whether specific formulation technologies (hydrogel, liposomal, phytosomal, nanoemulsion) rank consistently for fisetin efficacy. Head-to-head trials do not exist.
Bottom line
Liposomal fisetin is a legitimate pharmaceutical strategy for addressing fisetin’s poor oral bioavailability. The general case for enhanced formulations is strong — proven in humans for the hydrogel-formulated Krishnakumar 2022 product. But liposomal encapsulation specifically may change fisetin’s pharmacology from senolytic to senomorphic, based on the 2025 Molagoda cell-culture study. This is not a minor kinetic point — it changes what fisetin does at the cellular level. Readers pursuing senescent-cell clearance may be better served by unformulated pulsed protocols. Readers pursuing general SASP suppression may benefit from liposomal daily dosing. Neither choice is fully evidence-based; both are defensible. The most important editorial point is that "liposomal fisetin" is not simply a better version of the same drug — it may be a pharmacologically different drug. Read marketing claims with that in mind. For the broader context, see our dedicated bioavailability article and senolytic article.
Frequently asked questions
Is liposomal fisetin better than regular fisetin?
For bioavailability, likely yes. For senolytic activity specifically, possibly not — the 2025 Molagoda cell-culture study suggested liposomal encapsulation may shift fisetin’s pharmacology from senolytic to senomorphic (3). "Better" depends on your specific goal.
Does liposomal fisetin actually cross the blood-brain barrier?
Fisetin (in any form) crosses the blood-brain barrier in mice. Whether liposomal encapsulation improves brain delivery in humans is not directly measured. Liposomal formulations of other drugs have shown improved CNS penetration in some contexts.
How much liposomal fisetin should I take?
There is no established dose-equivalence between liposomal and unformulated fisetin in humans. If bioavailability is 20-fold higher, in principle 1/20th the dose would produce equivalent plasma concentrations — but the shift in pharmacology means equivalent plasma concentrations may not produce equivalent effects. Product-specific dosing guidance is not evidence-based.
Is there a difference between liposomal, phytosomal, and nano fisetin?
Yes, technically. Liposomal fisetin uses lipid bilayer vesicles. Phytosomal fisetin uses phospholipid complexes. Nano formulations vary widely — nanoemulsions, polymeric nanoparticles, cyclodextrin inclusion complexes. Each has different pharmacokinetic and pharmacological profiles. The marketing term "enhanced bioavailability fisetin" covers all of these.
Should I take liposomal fisetin daily or in pulses?
If the liposomal formulation is functioning as a senomorphic (as the 2025 Molagoda data suggest), daily dosing at a lower dose makes pharmacological sense — senomorphic activity requires sustained exposure. If you want senolytic activity specifically, an unformulated capsule in the trial-aligned pulsed pattern may be more appropriate.
Are any liposomal fisetin products backed by clinical trials?
As of 2026, no specific commercial liposomal fisetin product has been tested in a completed and published randomised human trial for a clinical endpoint.
References
1. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
2. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
3. Molagoda IMN, Sanjaya SS, Athapaththu AMGK, et al. Fisetin-loaded liposomes suppress senescence-associated secretory phenotype in senescent human dermal fibroblasts: a shift from senolytic to senomorphic activity. Antioxidants (Basel). 2025;14(7):864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12347707/
4. Ragelle H, Crauste-Manciet S, Seguin J, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm. 2012;427(2):452-459. https://pubmed.ncbi.nlm.nih.gov/22387278/
5. Kadari A, Gudem S, Kulhari H, et al. Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles. Drug Deliv. 2017;24(1):224-232. https://pubmed.ncbi.nlm.nih.gov/28156166/
6. Feng C, Yuan X, Chu K, et al. Preparation and optimization of poly(lactic acid) nanoparticles loaded with fisetin to improve anti-cancer therapy. Int J Biol Macromol. 2019;125:700-710. https://pubmed.ncbi.nlm.nih.gov/30521925/
7. Talebi M, Talebi M, Farkhondeh T, et al. New insights into the role of fisetin’s therapeutic effects on cancers, inflammation, and neurodegeneration. Nutr Neurosci. 2022;25(11):2317-2333. https://pubmed.ncbi.nlm.nih.gov/34281485/
8. Niedernhofer LJ, Robbins PD. Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases. Mech Ageing Dev. 2024;220:111995. https://doi.org/10.1016/j.mad.2024.111995